A humanized murine monoclonal antibody directed to the Fc R1-binding domain of human IgE (rhuMAb-E25) has been shown to inhibit the binding of IgE to mast cells without provoking mast cell activation. To examine the effects of neutralizing IgE on allergic airway responses
Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response
L
Inhaled allergens, acting through IgE-dependent mechanisms, are important triggers of asthma symptoms and inducers of airway hyperresponsiveness and airway inflammation. The effect of anti-IgE recombinant humanized monoclonal antibody-E25 (rhuMAb-E25) on the provocation concentration of allergen causing a 15% fall in FEV 1 (allergen PC 15 ) during the allergen-induced early asthmatic response (EAR) was assessed in a multicenter, randomized, double-blind, parallel group study. Ten of 11 allergic asthmatic subjects randomized to receive intravenous rhuMAb-E25, 2mg/kg on study day 0 and 1mg/ kg on
, and 70 completed the study; nine received intravenous placebo. The allergen PC 15 The role of IgE in induction, maintenance and asthma, but the role of pollens in triggering acute episodes seems less certain. Admissions to hospital are in triggering of asthma The link between allergy and asthma is long established fact lower during the hay fever season than in the three months preceding or following the UK grass pollen and the majority of patients with asthma have evidence of IgE mediated hypersensitivity to airborne allergens. 1 season, but it seems likely that fragmented pollen grains may be responsible for the epidemics of acute asthma This is especially true of children with asthma, among whom over 85% will show positive skin tests to one or associated with thunderstorms. 7 Allergen avoidance has been advocated in asthma and more airborne allergens. 2 3 On the other hand, a significant proportion of adult asthmatic subjects have can lead to modest reductions in non-specific bronchial responsiveness 8 but only extreme forms of avoidance negative skin tests and no obvious external trigger factors other than viral infections. 4 This group of "intrinsic" have had any significant clinical benefit. 9 In the context of occupational asthma where complete allergen avoidasthmatics often have quite severe disease and may respond less well to conventional drug therapy than ance is definitely achievable, it is clear that some patients improve markedly on ceasing exposure but others conthose with obvious allergies. While IgE mediated allergy is clearly an important risk factor for the development tinue to have asthmatic symptoms for many years, even though they are no longer exposed to the allergen of childhood asthma, it is less clear how important allergic triggers are in exacerbations of the disease or that induced their asthma. 10 Factors that have been associated with the persistence of occupational asthma in the maintenance of ongoing asthma. In children exacerbations of asthma have been shown to correspond include the duration of exposure before developing symptoms, the duration of continuing exposure after with episodes of viral upper respiratory tract infection, with over 85% of exacerbations linked temporally to the onset of asthma, and the persistence of airways eosinophilia. 11 So while it remains an article of faith that identifiable viral infections. 5 This relationship is also seen in adults although the proportion of asthma exreductions in allergen load are likely to be helpful in reducing the inflammatory process in allergic asthma, acerbations in which rhinoviruses can be identified is rather lower at around 50%. 6 Anecdotally, exposure to it seems likely that other factors also contribute to the maintenance of established allergic inflammation. cats or horses can trigger severe acute episodes of 
cell that recognises the MHC-antigen fragment complex meets the antigen-presenting B cell, the T cell antigen receptor is activated, sending internal signals to the cell to produce autocrine growth factors (for example, IL-2) as well as activating adhesion mechanisms to lock the two cells together. If the T cell is preprogrammed to facilitate IgE switching (that is, a Th2 cell), then IL-4 is also produced; this has autocrine effects as well as inducing transcription of the Ce immunoglobulin gene in the B cell (germline transcripts). Upon activation the T cell expresses CD40 ligand, which binds to CD40 on the B cell surface and provides the second signal needed to switch the B cell over to IgE production. Meanwhile, the B cell displays the B7 counter-receptor which signals via CD28 on the T cell to augment IL-4 production. Under these twin influences the B cell germline DNA is rearranged, with excision of the intervening immunoglobulin DNA and the production of mature IgE transcripts.
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Much attention has been focused on the role of the of IL-5, while upregulation of IL-4 is perhaps more closely related to IgE and allergic sensitisation but not cytokines IL-4 and IL-5 in coordinating the inflammatory response in asthma. IL-4 provides a key directly to the clinical syndrome of asthma. 27 Experimental studies of the role of IL-4 and IL-5 in signal in the process by which B cells switch over from making IgM or IgG antibodies towards making IgE.
allergic disease have been hampered by the lack of a really good animal or in vitro model of asthma. There This process of "isotype switching" is tightly controlled. On initial exposure to antigens the naive B cell can are many models of allergic sensitisation and it is relatively easy to demonstrate that sensitised animals will make IgA or IgM antibodies without requiring help from T cells. Concurrently, there is expansion of "memory" B develop airways eosinophilia and increased airways resistance, but these are essentially models of acute allercells recognising parts of the antigen. Upon subsequent exposure memory B cells can process antigen and can gen exposure rather than models of the disease we recognise as asthma. In particular, almost none of the use their surface MHC class II molecules to present antigenic fragments to T cells, thereby obtaining help models give any long lasting airways inflammation or anything similar to the airways remodelling and collagen from T cells for making a secondary immune response (fig 1) . In individuals predisposed to making IgE redeposition that occur in chronic human asthma. With these caveats, animal models have shown that T cells sponses T cells may be skewed towards production of IL-4 and IL-5 (the so-called Th2 phenotype) and if are the main source of IL-5, but not IL-4, in the lungs of antigen-challenged mice. 28 Detailed discussion of such a T cell interacts with a memory B cell, then the B cell may be directed to switch over to make IgE. Two these studies can be found elsewhere 29 but it has been consistently shown that monoclonal antibodies directed separate signals are required: a contact signal delivered through the CD40 molecule and its ligand, and a soluble against IL-5 can prevent airways hyperresponsiveness in several species including mice, guinea pigs, and monsignal delivered by IL-4. 12 In man, but not in rodents, the cytokine IL-13 can substitute for IL-4.
13 IL-4 was keys. [30] [31] [32] originally thought to be produced exclusively by T cells but, when bronchial and nasal biopsy specimens were stained for IL-4 protein, it was found that IL-4 protein Immunotherapy for asthma Rather than attacking the messengers, could one not was present mainly in mast cells.
14 Mast cells release IL-4 when stimulated 14 : in atopic subjects this may lead try to intervene at the level of the IgE antibody? This was for many years considered to be the basis for to an IL-4-rich environment in the bronchial mucosa and hence to immune deviation towards the Th2 phenoclassical injection immunotherapy. The immunisation schedules for specific injection immunotherapy (SIT) type and a greater likelihood of switching to IgE on subsequent exposure to potential allergens.
were developed in the last years of the 19th and the first decade of the 20th centuries, long before the discovery of The cytokine IL-5 is intimately involved in the differentiation, maturation and activation of eosinophils. The IgE in 1967. During the 1920s and 1930s the concept of "blocking antibodies" was popularised by Coca and eosinophil is derived from a common granulocyte bone marrow precursor cell and differentiates sequentially Cooke and, indeed, it is true that SIT induces an increase in IgG antibodies directed against the injected under the influence of IL-3, GM-CSF and finally IL-5 to become a mature eosinophil. 15 IL-5 is also a selective allergen with a gradual decline in specific IgE titres after an initial increase. However, the beneficial effects of SIT activator of the mature eosinophil. 16 IL-5 is made by T cells but has also been found in mast cells, eosinophils, come on much more rapidly than the antibody changes and it is now generally believed that SIT must work by a and epithelial cells. [17] [18] [19] Although the genes for IL-4 and IL-5 are located very form of immune deviation, driving T cells away from the Th2 phenotype towards a Th1 phenotype. 33 close together on chromosome 5q31-33, recent evidence indicates that their expression is not coordinately regAlthough SIT is the treatment of choice for hymenoptera sensitivity and it retains a place in the manulated. 20 Expression of mRNA for IL-5 is a feature of both allergic and non-allergic asthma 21 and there is a close agement of allergic rhinitis, there is considerable doubt about its value in the management of asthma. Firstly, correlation between T cell activation and serum IL-5 concentrations in various forms of asthma. 22 there is less clarity about the importance of specific allergy in the expression of asthma; secondly, many A number of interesting insights into the relative contributions of IL-4 and IL-5 to asthma have emerged patients are multiply sensitised and SIT is a highly targeted therapy which only addresses the allergen used in studies of occupational asthma to isocyanates. Isocyanate asthma is a particularly interesting model which in the injections; thirdly, and most importantly, there is no doubt that patients with asthma are at much greater bridges the gap between atopic asthma, where exposure to the inciting allergen is lifelong, and intrinsic asthma risk of severe adverse reactions to SIT. Of the 27 UK fatalities associated with SIT between 1952 and 1985, where, as far as we can tell, extrinsic allergens and IgE are not involved. Typically, isocyanate asthma develops the precise indication for SIT was known in 17 cases, and 16 of these were being treated for asthma. 34 This after a latent period in which exposure occurs without symptoms. IgE antibodies cannot be directly implicated should be seen in the context that SIT was being given much more often for hay fever than for asthma. Similarly, but the histology of the bronchial mucosa is more or less identical to that seen in other forms of asthma. 23 24 in the confidential inquiry by the American Academy of Allergy and Immunology into deaths associated with In biopsy specimens taken from patients with chronic isocyanate asthma there was upregulation of mRNA SIT, almost all the fatal cases were being treated for asthma and the mode of death was catastrophic bronfor IL-5 but not for IL-4, while when such patients underwent bronchial challenge there was upregulation chospasm rather than circulatory collapse or other features of anaphylaxis. 35 of both cytokines. 25 To add further confusion, T cell clones derived from patients challenged with toluene diisocyanate were found to be predominantly CD8+ and secreted IL-5 but little or no IL-4.
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Why try anti-IgE? It was against this background that steps were taken to Taken together, this cytokine evidence indicates that the expression of asthma is closely linked to upregulation try to develop more general forms of immunological which may account for the persistent suppression of bodies crosslink IgE bound to basophils or mast cells, and this then triggers degranulation and anaphylactictotal and specific IgE. However, the production of IgE may be damped down as well. Another study using E25 type reactions. Indeed, this effect of anti-IgE is the basis of several standard assays of mast cell function. Thus, has recently been published in which E25 was given to 240 patients with allergic rhinitis. 43 Unlike the two index any therapy directed against IgE has to avoid crosslinking IgE antibodies bound to mast cells. The aparticles, 39 40 Casale et al used three different treatment regimes (two different doses intravenously, one subproach taken was to develop antibodies directed against that portion of the IgE molecule which binds to the cutaneously) plus corresponding placebo controls. The reduction in total and specific IgE concentrations was high affinity Fc receptor. Such an antibody should be able to bind free IgE molecules and then either remove dose dependent but IgE was suppressed completely in only 11 of the 180 subjects who received active therapy. the IgE from the circulation as immune complexes or else prevent the IgE from binding to the Fc receptor Both total and specific IgE remained low four weeks after the last infusion but IgE concentrations had returned to due to steric hindrance. Of course, such an antibody would not be able to remove IgE antibodies that were baseline by eight weeks after the last infusion.
The airways response to allergen challenge is known already bound to mast cells through the Fc receptor so the value of such an approach in abolishing IgE to depend on two principal parameters: the concentration of allergen-specific IgE and the degree of nonmediated reactions will depend on whether cell bound IgE turns over rapidly or remains bound to the mast specific bronchial reactivity. Indeed, this relationship is so tight that one can use skin test reactivity (a surrogate cells for a long time. 36 The development process followed by Genentech for of allergen-specific IgE) and methacholine sensitivity to predict, with a reasonable degree of confidence, the E25 and the parallel work by CIBA 37 took this concept and proceeded to generate monoclonal antibodies which dose of allergen required to induce a 20% fall in FEV 1 .
44
Given that E25 reduces total and specific IgE by 88-recognise the Fc RI binding site of IgE. Suitable mouse antibodies which bound free IgE but did not stain mast 89%, it was to be expected that there would be a reduction in allergen induced bronchospasm provided cells were developed and then "humanised" by retaining the antigen combining site and engineering this into a that IgE was not permanently bound to airways mast cells. It is noteworthy that E25 did not affect the imhuman immunoglobulin (IgG 1 ) molecule. 38 Once achieved, the antibody could be mass produced to yield mediate skin test reaction, indicating that IgE bound to skin mast cells was not displaced during the treatment sufficient quantities for use in man. The monoclonal antibody used in both of the index studies 39 40 binds period. Most interesting is the effect of E25 on nonspecific bronchial responsiveness, as this gives us some well to free IgE but does not degranulate mast cells, so there is no specific risk of triggering anaphylaxis by indication of the degree to which background allergen exposure may be increasing the irritability of the bronchi. causing widespread release of mast cell mediators. The antibody has been tested in atopic and non-atopic vo-A twofold improvement in sensitivity was observed, which is modest, although it is clear from the paper that lunteers and is non-immunising in the sense that it does not induce antibodies directed against human IgG or there was considerable interindividual variation in the extent of improvement, implying that some subjects (so far) significant amounts of antibody directed against the anti-IgE combining site. Prior experience with improved a lot while others did not change at all.
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In the rhinitis study mentioned above, symptom monoclonal antibody therapies suggests that "anti-idiotypic" antibodies may well develop with prolonged use scores were proportional to the residual concentrations of ragweed specific IgE, but there were no overall as the human immune system should be tolerant of the constant part of IgG but does not have any system for statistically significant differences in symptom scores between the five treatment groups. 43 This study tells us specific tolerance to the idiotype (the specific antigenic features of the antibody combining site). Indeed, crossthat there may be a clinical effect on allergic rhinitis provided one can eliminate circulating allergen specific recognition of idiotypes has long been considered an advantageous feature of the immune system, allowing IgE, but it cannot be assumed that asthma will necessarily respond in the same way since, even though downregulation of clones that become overexpressed and encouraging diversity within the antibody repasthma and rhinitis share some common basic mechanisms, the mechanisms of disease expressions are quite ertoire. 41 One feature of E25 that may not be instantly obvious is that, although it will not bind to surface IgE that is bound to Fc RI, it does have the potential for modulating or eliminating other cells bearing IgE which express the lower affinity IgE receptor (Fc RII or CD23). CD23 is expressed by B cells, platelets, eosinophils, and some T cells and binds to IgE through a completely separate site on the Fc portion of IgE 42 so the E25 binding site should, at least theoretically, still be accessible and allow E25 to bind and eliminate those effector cells which bear FC RII.
What do the index papers really tell us and is E25 a viable therapy for asthma?
The two recent papers show firstly that E25 dramatically 
